PT  - JOURNAL ARTICLE
AU  - Olga Arkhipova
AU  - Tamila Martynyuk
AU  - Ludmila Samoilenko
AU  - Vladimir Sergienko
AU  - Irina Chazova
TI  - Quantitative estimation of lung perfusion scintigraphy in patients with idiopathic pulmonary arterial hypertension, receiving bosentan treatment
DP  - 2013 Sep 01
TA  - European Respiratory Journal
PG  - P2612
VI  - 42
IP  - Suppl 57
4099  - http://erj.ersjournals.com/content/42/Suppl_57/P2612.short
4100  - http://erj.ersjournals.com/content/42/Suppl_57/P2612.full
SO  - Eur Respir J2013 Sep 01; 42
AB  - Aim: To assess 12 wk bosentan therapy influence on lung perfusion with technetium-99mm macroaggregated albumin in pts with idiopathic pulmonary arterial hypertension (IPAH).Methods: The study included 15 pts with IPAH: 13 f/2m, mean age 40,4±11,9 yrs, functional classes (WHO FC) II-III, mean disease duration 2,9±2,5 yrs. All pts accepted Bozentan in a dose of 125 mg at day. After 4 wks Bozentan's dose was enlarged to 250 mg at day. 6-minute walking test (6MWT), right heart catheterization (RHC), lung scanning with 111-MBq dose of 99mTc-labeled macroaggregated albumin were performed at baseline and after 12 wks of therapy. Results: In all IPAH pts Bosentan therapy resulted in clinical and hemodynamic improvement. We found the significant increase of 6MWD (+48,8m); cardiac output (+0.8 l/min) by RHC, decrease of mean pulmonary arterial pressure (-7,8 mm Hg), pulmonary vascular resistance (-627 din*sec/sm5). We didn't detect significant changes of lung perfusion.View this table:Lung perfusion after bosentan 12-wks treatment Conclusions: In spite of significant improvement of functional capacity and hemodynamic parameters 12 wk bosentan therapy did not influence lung perfusion at pts with IPAH.